Title: Screening for ovarian cancer in women with varying levels of risk, using annual tests, results in high recall for repeat screening tests.
Authors: Nobbenhuis, Marielle AE
Bancroft, Elizabeth
Moskovic, Eleanor
Lennard, Fiona
Pharoah, Paul
Jacobs, Ian
Ward, Ann
Barton, Desmond PJ
Ind, Thomas EJ
Shepherd, John H
Bridges, Jane E
Gore, Martin
Haracopos, Chris
Shanley, Susan
Ardern-Jones, Audrey
Thomas, Sarah
Eeles, Rosalind A
Issue Date: 23-Nov-2011
Abstract: Abstract Background We assessed ovarian cancer screening outcomes in women with a positive family history of ovarian cancer divided into a low-, moderate- or high-risk group for development of ovarian cancer. Methods 545 women with a positive family history of ovarian cancer referred to the Ovarian Screening Service at the Royal Marsden Hospital, London from January 2000- December 2008 were included. They were stratified into three risk-groups according to family history (high-, moderate- and low-risk) of developing ovarian cancer and offered annual serum CA 125 and transvaginal ultrasound screening. The high-risk group was offered genetic testing. Results The median age at entry was 44 years. The number of women in the high, moderate and low-risk groups was 397, 112, and 36, respectively. During 2266 women years of follow-up two ovarian cancer cases were found: one advanced stage at her fourth annual screening, and one early stage at prophylactic bilateral salpingo-oophorectomy (BSO). Prophylactic BSO was performed in 138 women (25.3%). Forty-three women had an abnormal CA125, resulting in 59 repeat tests. The re-call rate in the high, moderate and low-risk group was 14%, 3% and 6%. Equivocal transvaginal ultrasound results required 108 recalls in 71 women. The re-call rate in the high, moderate, and low-risk group was 25%, 6% and 17%. Conclusion No early stage ovarian cancer was picked up at annual screening and a significant number of re-calls for repeat screening tests was identified.
Description: RIGHTS : This article is licensed under the BioMed Central licence at http://www.biomedcentral.com/about/license which is similar to the 'Creative Commons Attribution Licence'. In brief you may : copy, distribute, and display the work; make derivative works; or make commercial use of the work - under the following conditions: the original author must be given credit; for any reuse or distribution, it must be made clear to others what the license terms of this work are.
URI: http://www.dspace.cam.ac.uk/handle/1810/240688
Other Identifiers: http://dx.doi.org/10.1186/1897-4287-9-11
Appears in Collections:Scholarly works - Oncology

Files in This Item:

File Description SizeFormat
1897-4287-9-11.xml63.63 kBXMLView/Open
1897-4287-9-11.pdf230.21 kBAdobe PDFThumbnail
View/Open
Additional resources for this item
search for alternative versions in eresources@cambridge
retrieve citation metadata in EndNote format

This item has been accessed 260 times.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.